Industry News
Biotechnology Industry News
With the result falling short of…
With the result falling short of the bar Amgen set in another study, investors sent Zenas’ share price down 48% to $18 in premarket trading.
Aktis Oncology is aiming to bring…
Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026.
Sanofi has returned to U.S….
Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and immunology development pact.
The Singapore Eye Research…
The Singapore Eye Research Institute has pulled out of a collaboration with TME Pharma less than seven months after cementing their work on an eye disease program.
In 2025, biopharma layoffs showed…
In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year.
After five years, Nido Biosciences…
After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study.
AbbVie and Gilead each used the…
AbbVie and Gilead each used the holiday season to reward their pipelines with a new clinical-stage cancer drug.
Johnson & Johnson and Genmab…
Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the clinic.
Ultragenyx Pharmaceutical has…
Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
As the biopharma wound down for…
As the biopharma wound down for the holidays, the company reported the failure of a midphase study of BHV-7000 for the treatment of major depressive disorder.
The festive period brought some…
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the companies’ respective drug applications.
Zai Lab President and COO Josh…
Zai Lab President and COO Josh Smiley explains how speed, scale and rigor are reshaping global drug development
Cardiovascular (CV) disease is a…
Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer.
Windtree Therapeutics has not been…
Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal means stepping outside the world of drug development. Now, the company is further divesting itself from
William Blair has hand-picked its…
William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage biotechs in the bunch.
Hope Biosciences has linked its…
Hope Biosciences has linked its stem cell therapy candidate to improved motor function in Parkinson’s disease patients in a phase 2 trial.
Despite a year of trade tensions,…
Despite a year of trade tensions, national security strictures and stark warnings about the United States’ waning biotech innovation edge, the fact remains that China is and will likely continue to be a prominent source
Six people, including a former…
Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an alleged $41 million insider trading and stock manipulation scheme that involves two biotech companies.
Amid news of the splashy $4.8…
Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic lung disease candidate it had once hoped would become a best-in-class treatment.
Two years after Gilead secured the…
Two years after Gilead secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to pick the first fruits from the pact.